Suxia Luo
Henan Cancer Hospital · Henan Tumor Hospital · Study Principal Investigator
Built from public records under this name as ClinicalTrials.gov spells it. A name can belong to more than one person, so each section says how its rows were tied to this name. No contact details are shown.
Trials
Studies that name Suxia Luo as principal investigator, study chair or study director, newest first. Live from ClinicalTrials.gov, fetched 2026-11-12 00:08 UTC. Open this list on ClinicalTrials.gov
- Ph4NCT06897917 · Real World Study of Oxycodone/Naloxone Sustained-Release Tablets (Mimeixin) for Patients With Severe Cancer PainHenan Cancer Hospital · not yet recruiting · Opioid-Induced Constipation, Pain Cancer · principal investigator
- Ph1NCT06761651 · A Study of TAVO412 in Patients with Cancer (TAVO412)Tavotek Biotherapeutics · recruiting · Cancer · principal investigator
- Ph1NCT06521931 · A Study of PN20 for the Prevention of Chemotherapy-induced Thrombocytopenia in Lymphoma or Solid Tumor PatientsChongqing Peg-Bio Biopharm Co., Ltd. · completed · Thrombocytopenia · principal investigator
- N/ANCT06335147 · PD1 Antibody Combined With mFOLFOX6 Neoadjuvant Therapy for Advanced Resectable Metastatic Colon CancerHenan Cancer Hospital · unknown · Metastatic Colon Cancer · principal investigator
- Ph1NCT06258408 · A Phase 1 Study of BB102 in Participants With Advanced Solid TumorsBroadenbio Ltd., Co. · recruiting · Advanced Solid Tumor · principal investigator
- Ph1NCT06139536 · Assessment of Safety, Tolerability and Pharmacokinetics With BAT4706 and BAT1308 in Advanced Solid Tumors PatientsBio-Thera Solutions · completed · Advanced Solid Tumor · principal investigator
- Ph2NCT05265052 · 3D1002 in Combination With Oxycodone Hydrochloride Sustained-release Tablets in Patients With Moderate to Severe Cancer Pain3D Medicines · not yet recruiting · Cancer Pain · principal investigator
- Ph1NCT05155722 · Assessment of Safety ,Tolerance and Pharmacokinetics Clinical Efficacy With BAT1308 in Advanced Solid TumorsBio-Thera Solutions · completed · Advanced Solid Tumor · principal investigator
- Ph1NCT05072522 · A Study of SKLB1028 in Patients With Advanced Solid TumorCSPC ZhongQi Pharmaceutical Technology Co., Ltd. · unknown · Advanced Solid Tumors · principal investigator
- Ph1NCT05042908 · Evaluation of LBL-003 Phase I Study in Patients With Advanced MalignanciesNanjing Leads Biolabs Co.,Ltd · completed · Advanced Malignant Tumor · principal investigator
- Ph2NCT05013697 · TQB2450 Solution for Injection (TQB2450)+Paclitaxel+Cisplatin ± Anlotinib in the Treatment of Esophageal Cancer.Henan Cancer Hospital · unknown · Esophageal Neoplasms · study chair
- Ph1NCT04615312 · A Trail of CDK4 / 6 Inhibitor and MEK Inhibitor in the Treatment of Metastatic Digestive System TumorsHenan Cancer Hospital · unknown · Digestive System Tumors · principal investigator
- Ph1NCT04478461 · Safety, Tolerability, and Pharmacokinetics of MW11 in Patients With Advanced Solid TumorsMabwell (Shanghai) Bioscience Co., Ltd. · unknown · Advanced Solid Tumor · principal investigator
- Ph2NCT04430361 · the Efficacy and Safety of 5-HT3 Receptor Antagonist, Dexamethasone or Megestrol Acetate Dispersible Tablets in the Control of Nausea and Vomiting Induced by Highly Emetogenic ChemotherapyHenan Cancer Hospital · unknown · Tumor, Chemotherapy-induced Nausea and Vomiting · principal investigator
- Ph3NCT04351867 · A Clinical Trial of Two Adjuvant Chemotherapy Regimens for Postoperative Gastric CancerLiNing · unknown · Stomach Neoplasms · principal investigator
- Ph1NCT04326296 · The Safety and Tolerability of PD-L1 Monoclonal Antibody Plus Lenalidomide in The Treatment of Colorectal CancerLiNing · unknown · Colorectal Neoplasms · principal investigator
- Ph1NCT04087252 · An Immunogenic Personal Neoantigen Vaccine for Cancer TreatmentHenan Cancer Hospital · unknown · Cancer · principal investigator
- Ph2NCT03950271 · SHR-1210 Combined With Trastuzumab , Oxaliplatin and Capecitabine for Neoadjuvant Therapy of Gastric Adenocarcinoma/Gastroesophageal Junction AdenocarcinomaHenan Cancer Hospital · active not recruiting · Gastric Cancer · principal investigator
- N/ANCT03478943 · The Real World Study of Apatinib for Gastric Cancer Treatment in Henan ProvinceHenan Cancer Hospital · unknown · Gastric Cancer · principal investigator
- Ph2NCT03397199 · Study of Apatinib Plus S-1 as the Therapy of Advanced Colorectal CancerHenan Cancer Hospital · unknown · Colorectal Cancer · principal investigator
Grants
NIH projects from RePORTER, fetched 2026-11-12 00:08 UTC. A project is listed only when its grant number is on one of the trials above, or when the awardee institution matches an affiliation the registry gives for this name. Coverage is US federal funding only; UK and EU funders are not searched yet.
No NIH project could be tied to this name by a shared trial or a matching institution.
Most cited trial papers
Clinical-trial papers with this author name, ranked by citations from NIH iCite, fetched 2026-11-12 00:08 UTC. The ranking covers the 200 most relevant of 228 PubMed records, and a shared surname and initials can bring in a namesake. All 228 on PubMed
- A Trial of Lopinavir-Ritonavir in Adults Hospitalized with Severe Covid-19.N Engl J Med · 20203,522 citationsRCR 201.4
- 700 citationsRCR 60.3
- 392 citationsRCR 33.0
- Neoadjuvant PD-1 blockade with toripalimab, with or without celecoxib, in mismatch repair-deficient or microsatellite instability-high, locally advanced, colorectal cancer (PICC): a single-centre, parallel-group, non-comparative, randomised, phase 2 trial.Lancet Gastroenterol Hepatol · 2022265 citationsRCR 16.1
- 223 citationsRCR 16.6
- 219 citationsRCR 9.2
- Reversing drug resistance of soft tumor-repopulating cells by tumor cell-derived chemotherapeutic microparticles.Cell Res · 2016202 citationsRCR 6.3
- Growth hormone activates PI3K/Akt signaling and inhibits ROS accumulation and apoptosis in granulosa cells of patients with polycystic ovary syndrome.Reprod Biol Endocrinol · 2020199 citationsRCR 12.3
- 193 citationsRCR 16.8
- Efficacy and safety of a novel anti-HER2 therapeutic antibody RC48 in patients with HER2-overexpressing, locally advanced or metastatic gastric or gastroesophageal junction cancer: a single-arm phase II study.Cancer Commun (Lond) · 2021185 citationsRCR 9.8